Moving away from traditional clinical categories of MS may lead to better, and more personalised treatments for MS.
Dr Giacomo Boffa receives the 2021 Young Investigator Award on his project on using aHSCT in individuals with secondary progressive MS
An important milestone for people with secondary progressive MS in Europe
An international study helps clinicians identify people who are at high risk of developing secondary progressive MS at an earlier stage.
FDA approves cladribine for people with relapsing forms of MS and active secondary progressive MS
FDA approves the drug Siponimod, to treat people with active secondary progressive MS
Results from a trial of natalizumab in secondary progressive MS suggest anti-inflammatory treatments could slow disability accumulation, even after significant function has been lost.
A new study recently published uses ‘real-world’ data to investigate the effects of disease modifying therapies on secondary progressive MS
MS comes in several forms, including clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS and primary progressive MS.